TKT Announces Resignation of Daniel E. Geffken as Chief Financial Officer

Search Blogs that Mention this News Release

Click this link to view linked Bookmarking Services

Click this link to view linked Blogging Services

TKT Announces Resignation of Daniel E. Geffken as Chief Financial Officer

		TRANSKARYOTIC THERAPIES LOGO - TKT Transkaryotic Therapies Inc. logo. (PRNewsFoto)[JL] CAMBRIDGE, MA USA

    CAMBRIDGE, Mass., April 4 /PRNewswire-FirstCall/ --
Transkaryotic Therapies, Inc. (Nasdaq: TKTX) today announced that Daniel E.
Geffken has resigned as Senior Vice President, Finance and Chief Financial
Officer of TKT, effective April 18, 2003.
    "Over the past six years, Dan was a key part of the senior management team
and spearheaded TKT's fundraising activities that were used to develop our
product pipeline and launch Replagal in Europe.  We are grateful for all his
contributions," said Mr. Michael J. Astrue, President and Chief Executive
Officer of TKT.  "Dan will be missed by his colleagues and we wish him success
in the future."
    Prior to joining TKT in February 1997, Mr. Geffken, 46, was Vice President
and Chief Financial Officer of CytoTherapeutics, Inc. and held positions at
The Andersen Group, Inc., MedChem Products, Inc. and KPMG Peat Marwick.
During his eleven years in the biotechnology industry, he has raised more than
$600 million in debt and equity financings.  He received a B.S. in Economics
from The Wharton School, University of Pennsylvania and an M.B.A. from Harvard
Business School.  Mr. Geffken serves on the Board of Directors of Shelter,
Inc., a non-profit organization providing services and housing for the
homeless, and BioValve Technologies, Inc., a privately held drug delivery
company.

    TKT is a biopharmaceutical company developing therapeutics for the
treatment of rare genetic diseases caused by protein deficiencies.  The
company currently markets one product, Replagal (agalsidase alfa) for the
treatment of Fabry disease, in the European Union and certain other countries.
TKT is headquartered in Cambridge, Massachusetts and has a majority-owned
subsidiary in Sweden, TKT Europe-5S AB, which is responsible for European
sales and marketing activities for Replagal.  Additional information on TKT is
available on the company's website at http://www.tktx.com.

    This press release contains forward-looking information regarding TKT's
management structure, as well as statements containing the words "believes,"
"anticipates," "plans," "expects," "will," and similar expressions.  There are
a number of important factors that could cause the company's actual results to
differ materially from those indicated by such forward-looking statements,
including whether TKT will be able to recruit and retain a qualified Chief
Financial Officer, and other factors set forth under the caption "Risk
Factors" in the company's Annual Report on Form 10-K for the year ended
December 31, 2002, which is on file with the Securities and Exchange
Commission and are incorporated herein by reference.  The company does not
undertake any obligation to update any forward-looking statements.

   Replagal(TM) is a trademark of Transkaryotic Therapies, Inc.

    CONTACT:
     Justine E. Koenigsberg
     Director, Corporate Communications
     (617) 349-0271

SOURCE Transkaryotic Therapies, Inc.

http://www.tktx.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:

http://www.prnewswire.com/comp/120657.html
CONTACT:
Justine E. Koenigsberg, Director, Corporate
Communications of Transkaryotic Therapies, Inc., +1-617-349-0271